Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
Date:11/1/2007

/p>

restructuring were the decisions to discontinue further development of

ANA380, a nucleotide analog for the treatment of hepatitis B virus

(HBV) infection, halt all work on early discovery projects, and effect

an immediate reduction in force of approximately one-third of the

Company's employees, with several additional positions to be eliminated

in early 2008.

Recent Scientific Presentations

-- Reported ANA773 Dose Schedule Data. On October 25, 2007, Anadys

presented preclinical data on ANA773 during a poster session at the

2007 AACR-NCI-EORTC International Conference on Molecular Targets and

Cancer Therapeutics. The report showed the impact that varying the

dosing schedule has on the pharmacodynamic response to ANA773, a

prodrug of a toll-like receptor 7 agonist. Specifically, the report

described that immunostimulatory responses to ANA773 in vivo can be

modulated by schedule of administration.

-- Reported ANA598 Preclinical Data. On September 11, 2007, Anadys

presented preclinical data on ANA598, a non-nucleoside inhibitor of the

HCV NS5B polymerase, during a poster session at the 14th International

Symposium on Hepatitis C Virus and Related Viruses. The report

characterized the favorable antiviral, metabolic, pharmacokinetic and

preliminary toxicologic properties that supported the decision

announced in June to progress ANA598 to IND enabling studies and

subsequent clinical evaluation expected to commence in the second

quarter of 2008.

Webcast of Conference Call

Anadys will host a conference call today at 5:00 p.m. Eastern Daylight Time to discuss its third quarter financial results and operational highlights and to give an update on its programs. A live webcast of the call will be available online at '/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... (PRWEB) October 30, 2014 On ... Cellular Medicine Showcase in Chicago, leading applied stem ... Surgeon, Dr. Wade McKenna presented talks on New ... Orthopedic Surgical Applications For Stem Cells. , Dr. ... membrane and the properties of AlphaGEMS that include: ...
(Date:10/30/2014)... Spartan Bioscience announced today that Health ... . It detects CYP2C19 genetic mutations in less than ... Spartan RX CYP2C19 System is the first near-patient DNA ... Canada. Due to the system’s ease of use, Health ... healthcare professionals such as doctors, nurses, pharmacists, and laboratory ...
(Date:10/30/2014)... Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), the leader ... company overview at the Nomura Biotechnology Conference on Thursday, November ... MA. A live webcast of the ... of the Company,s website, www.isispharm.com .  A replay will ... will be archived for a limited time. About ...
(Date:10/30/2014)... 29, 2014) – The severe flooding that devastated a ... less destructive if the bridges, roads and other infrastructure ... study from the University of Colorado Denver. , "People ... said Jimmy Kim, PhD, associate professor of structural engineering ... Science and lead author the study. "There is an ...
Breaking Biology Technology:Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2CU Denver study says upgrading infrastructure could reduce flood damage 2
... SAN DIEGO, March 12 Sangart, Inc., a privately ... commercialization of oxygen therapeutics, today announced the receipt of ... This investment results from the exercise of warrants issued ... round initiated in 2007. The most recent investment ...
... 12 The United States, long the beneficiary of ... workers from leaving to pursue expanding opportunities in their ... 2009 Issues in Science and Technology .In ... Duke University and Harvard Law School, writes that ...
... March 12 Boston Scientific Corporation (NYSE: ... raised the Company,s rating outlook to stable from negative. ... bond rating to Ba1 from Ba2 and its liquidity ... credit rating at Ba1. Moody,s said the revised ...
Cached Biology Technology:Sangart, Inc. Completes Series F Funding Round 2U.S. Risks Losing Highly Skilled Immigrants 2U.S. Risks Losing Highly Skilled Immigrants 3Moody's Raises Boston Scientific's Rating Outlook to Stable 2Moody's Raises Boston Scientific's Rating Outlook to Stable 3
(Date:10/28/2014)... of the tragic realities of cancer is that ... toxic and their effectiveness varies unpredictably from patient ... poised to change this reality by rapidly assessing ... an individual,s cancer before chemotherapy begins. , A ... by Assistant Professor Melissa Skala has developed the ...
(Date:10/28/2014)... Singapore (NUS) have discovered a new reproductive mode in ... eggs in live bamboo with narrow openings - which ... ( Raorchestes chalazodes ). This critically endangered frog is ... this novel reproductive strategy. The findings were published in ... the Linnean Society , in October 2014. , ...
(Date:10/27/2014)... researchers have delivered a scientific one-two punch with a ... self-assemble via their sticky ends. , Collagen is the ... bone and the fibrous tissues that support cells and ... better synthetic collagen for tissue engineering and cosmetic and ... has been studying synthetic collagen for a decade, teasing ...
Breaking Biology News(10 mins):Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3NUS researchers discover for the first time that a rare bush frog breeds in bamboo 2NUS researchers discover for the first time that a rare bush frog breeds in bamboo 3'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3
... allowing us to spot prey, vision keeps many animals, including ... and why is it easier for us to spot movement ... notice other things? The complexity of the neural network that ... new technology and support from the National Science Foundation, Claire ...
... One of the many advantages of maintaining a normal ... a healthy heart. Fat tissue is increasingly seen as more ... secretory organ that normally produces high levels of a cardioprotective ... people has long been a mystery, and now a team ...
... developing a cost-effective electronic monitoring system that will enable ... by allowing users to track water-quality data from these ... National Science Foundation (NSF) grant. "Our goal is ... conditions in the Chesapeake Bay, the sounds of North ...
Cached Biology News:The zebrafish's neural circuit prevents it from biting off more than it can chew 2Study finds fat hormone's long-sought link to heart protection 2Researchers developing real-time electronic monitoring for coastal waters 2
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
...
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
... is a sample preparation kit for reduction ... of detergents, phenolic compounds, salts, and most ... samples. The kit procedure involves a TCA-like ... or cells, plant leaves, E. coli, and ...
Biology Products: